THERATECHNOLOGIES INC (TH.CA) Stock News

TSX:TH - CA88338H7040 - Common Stock

4.45 CAD

-0.02 (-0.45%)

Last: 8/29/2025, 7:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TH.CA Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Theratechnologies - Mentions: THTX

Theratechnologies annonce le dépôt des documents relatifs à l’assemblée extraordinaire et l’obtention d’une ordonnance provisoire concernant son acquisition par CB Biotechnology, un membre du même groupe que Future Pak

14 days ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak

14 days ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak

2 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies présente ses résultats financiers pour le deuxième trimestre de 2025

2 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Reports Financial Results for the Second Quarter 2025

2 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Reports Financial Results for the Second Quarter 2025

2 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies annoncera ses résultats financiers du deuxième trimestre de l’exercice financier de 2025

2 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies to Announce Second Quarter 2025 Financial Results

2 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies to Announce Second Quarter 2025 Financial Results

2 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies conclut un accord définitif en vue de son acquisition par CB Biotechnology, un membre du même groupe que Future Pak

2 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

2 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

3 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Reports on its Annual Meeting of Shareholders

3 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies rend compte de son assemblée annuelle des actionnaires

3 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Reports on its Annual Meeting of Shareholders

4 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies présente à la conférence ACTHIV 2025 de nouvelles données soulignant l’importance de prendre en charge l’excès de graisse viscérale abdominale chez les personnes vivant avec le VIH

4 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

4 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Provides Update on Sale Process

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies fait le point sur le processus de vente

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Provides Update on Sale Process

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies réagit à la récente déclaration publique de Future Pak et annonce des discussions exclusives avec un autre acquéreur potentiel pour la vente de la Société

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies présente ses résultats financiers pour le premier trimestre de 2025 et passe en revue ses principales réalisations

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies annoncera ses résultats financiers du premier trimestre de l’exercice financier de 2025 et fera une mise à jour de ses activités

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies reçoit l’approbation de la FDA pour EGRIFTA WR(MC) (la formulation F8 de la tésamoréline) pour traiter l’excès de graisse viscérale abdominale chez les adultes vivant avec le VIH atteints de lipodystrophie

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

5 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

6 months ago - By: Theratechnologies - Mentions: THTX

La présentation de Therachnologies lors de la CROI met en évidence les limites liées à l’utilisation de l’IMC pour évaluer le risque de maladie cardiovasculaire (CV) chez les personnes vivant avec le VIH

6 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

6 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies présente des données de suppression virologique encourageantes provenant de l’essai PROMISE-US portant sur l’ibalizumab lors de la CROI

6 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

6 months ago - By: Theratechnologies - Mentions: THTX

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI